InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Receives MHRA Approval to Launch Second Phase 3 Trial for CYB003 in Depression
July 17, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, announced UK MHRA approval to initiate EMBRACE, the second pivotal trial in its Phase 3 PARADIGM program evaluating CYB003, a proprietary deuterated psilocin analog for Major Depressive Disorder (MDD). CYB003 previously received Breakthrough Therapy Designation from the U.S. FDA. EMBRACE will enroll 330 patients with […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expects SPC-15 PTSD Study Results Within 90 Days
July 7, 2025
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, announced it expects data from two key preclinical studies of its lead candidate SPC-15 within 30 to 90 days. SPC-15 is an intranasal prophylactic designed to boost stress resilience and prevent Post-Traumatic Stress Disorder (PTSD). The ongoing studies include IND-enabling GLP-compliant toxicology and toxicokinetic testing, as well […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures $50 Million in Convertible Debenture Financing from High Trail
July 2, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company developing next-generation psychedelic-based treatments, has closed a private placement with High Trail Special Situations LLC for $50 million in unsecured convertible debentures, as part of an agreement that allows for up to $500 million in total funding. The financing will support the advancement of Cybin’s […]
ONAR Holding Corp. (ONAR): Why Smart Agencies Are Choosing Algorithms Over Assumptions
June 26, 2025
The marketing technology sector finds itself at a crossroads that extends far beyond the typical innovation cycle. As adtech companies scramble to incorporate artificial intelligence into their offerings, launching everything from automated creative platforms to machine learning optimization tools, a critical distinction is emerging between organizations that deploy AI strategically versus those that implement it […]
InvestorNewsBreaks – Psyence Biomedical Ltd. (NASDAQ: PBM) to Present at Psychedelic Science 2025
June 18, 2025
Psyence Biomed (NASDAQ: PBM) has announced that its Chief of Global Impact, Mary-Elizabeth Gifford, was selected as a featured speaker at Psychedelic Science 2025 (“PS2025”) – the world’s largest international gathering focused on psychedelic research, biopharma, medicine, policy, and culture. Hosted by the Multidisciplinary Association for Psychedelic Studies (“MAPS”), the highly anticipated conference is taking […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Progress on Phase 3 Psychedelic Therapeutics Program
June 13, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) issued a corporate update emphasizing continued momentum in its clinical pipeline, including the advancement of its lead candidate CYB003 into Phase 3 development. CEO Doug Drysdale underscored the growing regulatory clarity around psychedelic therapeutics and expressed optimism that Cybin’s IP portfolio and clinical strategy position the company to help […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at H.C. Wainwright Neuro Perspectives Conference
June 12, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that Chief Executive Officer Doug Drysdale will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference, scheduled for June 16–17, 2025. The company is advancing next-generation neuropsychiatric treatments aimed at transforming mental healthcare. To view the full press release, visit https://ibn.fm/BjhYH About […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Receives USPTO Notice of Allowance for PTSD Treatment Patent
June 11, 2025
Silo Pharma (NASDAQ: SILO) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its licensed patent application related to biomarkers for evaluating prophylactic treatments for stress-induced affective disorders. The patent, set to be issued as U.S. Patent No. 12,329,726 on June 17, 2025, bolsters Silo’s intellectual property around its […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak on Pivotal Trials Panel at Psychedelic Science 2025
June 11, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will speak at the Psychedelic Science 2025 Conference, held June 16–20 in Denver. Drysdale will participate in the panel “The Home Stretch: Pivotal Trials and Preparing for Launch” on Thursday, June 19 at 9:30 a.m. MDT. He emphasized the importance of collaborative dialogue in […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB004 Anxiety Treatment Candidate
June 3, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company focused on next-generation mental health therapies, announced the issuance of U.S. patent 12,318,477 supporting its CYB004 program, a deuterated DMT candidate being developed for generalized anxiety disorder (“GAD”). The patent, which covers novel intramuscular formulations of DMT and related compounds, extends exclusivity through 2040. CEO […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Discuss Phase 3 Progress and Industry Trends in May 29 Fireside Chat
May 22, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will join a Water Tower Research Fireside Chat on May 29, 2025, at 11 a.m. ET. The discussion will cover Cybin’s CYB003 Phase 3 program, recent clinical partnerships, its collaboration with Thermo Fisher, and insights on the evolving regulatory landscape for psychedelics. The event […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with Nasal Spray Device Study for SPC-15
May 21, 2025
Silo Pharma (NASDAQ: SILO) announced a service agreement with Resyca BV to conduct a drug-device study on the microchip-enabled nasal spray system used in its lead PTSD treatment candidate, SPC-15. The study is intended to provide the final device data needed for an Investigational New Drug (IND) application to the FDA later this year. CEO […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Applauds FDA Support for Psychedelic Therapeutics, Advances Phase 3 Trials
May 20, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) welcomed recent comments from FDA Commissioner Dr. Martin Makary endorsing the accelerated development of psychedelic therapeutics. The company, which is conducting Phase 3 trials of CYB003 for major depressive disorder (MDD) and Phase 2 trials of CYB004 for generalized anxiety disorder (GAD), said the FDA’s openness validates its mission […]
Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform
May 19, 2025
Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes $2 Million Public Offering of Shares and Warrants
May 19, 2025
Silo Pharma (NASDAQ: SILO) a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed a public offering totaling approximately $2 million in gross proceeds. The offering included 3,333,338 shares of common stock or pre-funded warrants, along with Series A-1 and Series A-2 warrants, each allowing the purchase of up to 3,333,338 […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Prices $2 Million Public Offering of Common Stock and Warrants
May 16, 2025
Silo Pharma (NASDAQ: SILO) has priced a public offering of approximately 3.33 million shares of common stock (or pre-funded warrants) along with Series A-1 and Series A-2 warrants, all priced at $0.60 per unit. The Series A-1 and A-2 warrants are immediately exercisable at $0.60 per share, with expirations set at five years and eighteen […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Taps Thermo Fisher for Phase 3 and Commercial Production of CYB003
May 15, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) has partnered with Thermo Fisher Scientific to support Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin treatment for major depressive disorder (MDD). The agreement expands on Cybin’s existing U.S.-based manufacturing operations, with Thermo Fisher handling drug substance in South Carolina and capsule production […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Engages Veloxity Labs for IND-Enabling Study of PTSD Drug SPC-15
May 15, 2025
Silo Pharma (NASDAQ: SILO) has partnered with Veloxity Labs to conduct GLP-compliant bioanalysis for its ongoing toxicology and toxicokinetics study of SPC-15, an intranasal treatment aimed at preventing PTSD. The data will support an FDA investigational new drug submission expected in 2025. If approved, Silo plans to advance SPC-15 into a Phase 1 human clinical […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances PTSD Treatment with FDA-Requested Safety Study for SPC-15
May 14, 2025
Silo Pharma (NASDAQ: SILO) has partnered with Frontage Laboratories to conduct a 7-day safety and toxicology study of its lead asset, SPC-15, following a request from the FDA. The intranasal treatment targets PTSD and stress-related disorders, and the study is expected to strengthen Silo’s upcoming IND application. Silo remains on track for an FDA submission […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Alliance Global Partners Healthcare Showcase on May 21
May 14, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will participate in a fireside chat at the virtual Alliance Global Partners Healthcare Company Showcase on May 21, 2025. The session will be webcast live at 1:40 p.m. ET and later available via the company’s investor relations site. To view the full press release, […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB003 Depression Treatment
May 8, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced the issuance of U.S. patent 12,291,499 for its CYB003 program targeting major depressive disorder (MDD). The patent covers pharmaceutical compositions and oral dosage forms related to Cybin’s proprietary deuterated psilocin analog and offers exclusivity through 2041. The company is currently dosing patients in a Phase […]
NECANN Cannadelic Miami 2025 to Ignite Miami’s Wellness Evolution
May 6, 2025
Researchers, scholars, wellness seekers, and industry experts are invited to attend the NECANN Cannadelic Miami 2025, held at the Miami Airport Convention Center, Miami, FL, from May 23 to 24, 2025. This transformative two-day event empowers attendees to explore the frontiers of emerging therapies, plant-based medicine, and next-gen healing. Based on the inspiring theme “Elevate […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at Milken Global Conference on Medical Breakthroughs
May 1, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced that CEO Doug Drysdale will speak at the 28th Annual Milken Institute Global Conference on May 5 at 2:30 p.m. PDT. He will join the panel “The Global Landscape and Opportunities for Medical Breakthroughs” to discuss innovation in drug development and next-generation mental health treatments. The event will […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Preclinical Data for SP-26 Ketamine Implant
April 30, 2025
Silo Pharma (NASDAQ: SILO) today announced favorable preclinical results for SP-26, its novel extended-release ketamine implant aimed at treating fibromyalgia. Conducted in minipigs, the study met all endpoints, including safety, tolerability, and pharmacokinetics, with no implant-related adverse events and sustained ketamine release for up to 22 days. CEO Eric Weisblum said the results support SP-26’s […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Alzheimer’s Drug SPC-14
April 28, 2025
Silo Pharma (NASDAQ: SILO) announced the filing of a patent application with the U.S. Patent and Trademark Office for SPC-14, a novel intranasal compound exclusively licensed from Columbia University targeting cognitive and neuropsychiatric symptoms in Alzheimer’s disease. The patent covers SPC-14’s mechanism of action focused on glutamate receptor NDMAR and serotonin 5-HT4, with preclinical studies […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Phase 3 Trial Network to 18 Sites for CYB003 in Depression
April 23, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced the expansion of its strategic partnership agreements to include 18 U.S. clinical sites for its multinational Phase 3 trial of CYB003, a next-generation psychedelic-based therapy for major depressive disorder (MDD). The APPROACH study, part of Cybin’s PARADIGM program, is expected to grow to approximately 45 sites. By leveraging […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Forms Strategic Partnership With Osmind to Prepare for Mental Health Drug Commercialization
April 21, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, has entered a strategic partnership with Osmind, a technology and services provider with a network of over 800 U.S. psychiatry clinics. The collaboration aims to lay the groundwork for the commercialization of Cybin’s clinical programs CYB003, in Phase 3 for major depressive disorder, and CYB004, […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Final Preclinical Study for PTSD Treatment SPC-15
March 26, 2025
Silo Pharma (NASDAQ: SILO) announced the first dosing in a GLP-compliant toxicology and toxicokinetics study for its lead candidate, SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD). The study, part of an IND-enabling program, follows a pre-IND meeting with the FDA that aligned the company on the 505(b)(2) regulatory pathway, which may expedite approval […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures USPTO Patent for PTSD Treatment SPC-15
February 27, 2025
Silo Pharma (NASDAQ: SILO), a biopharmaceutical company developing novel therapeutics and drug delivery systems, announced that the U.S. Patent and Trademark Office (USPTO) has issued an Issue Notification for its patent application (No. 17/954,864), titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The patent, which is set to be issued on March 4, 2025, […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Provisional Patent for SPC-15 Dual-Action Treatment
February 18, 2025
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has filed a provisional patent application with the U.S. Patent and Trademark Office for its lead asset, SPC-15. The patent covers a dual-action method targeting stress-induced psychiatric behaviors through a combination of a serotonin type IV receptor agonist and an N-methyl-D-aspartate receptor antagonist. CEO Eric Weisblum emphasized […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Early Data on SP-26 Ketamine Implant Study
February 11, 2025
Silo Pharma (NASDAQ: SILO) announced encouraging early results from its ongoing study evaluating the pharmacokinetics, safety and tolerability of its SP-26 ketamine extended-release implant for chronic pain and fibromyalgia. The non-GLP study, launched in December 2024, marks the first small animal testing of SP-26, with dosing completed in early January. No serious side effects or […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Q3 Financials, Advances Clinical Programs
February 11, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) announced third-quarter financial results and recent developments in its neuropsychiatry pipeline. The company continues advancing its lead programs, including CYB003, which has entered a multinational Phase 3 trial for major depressive disorder, and CYB004, now in Phase 2 testing for generalized anxiety disorder. Financially, Cybin reported a net loss of […]
AI Alliance in Europe Announces LLM to Rival DeepSeek and Silicon Valley
February 3, 2025
As the AI dominance of Silicon Valley comes under attack from upstarts like DeepSeek, an alliance in Europe is planning to up the ante with its ambition to come up with European-grown alternatives that are as good as or even better than the existing artificial intelligence options. The project, dubbed OpenEuroLLM, aims to develop next-gen […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Bolsters Intellectual Property with New Patent Filing for PTSD Treatment
January 22, 2025
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, has filed a provisional patent application with the U.S. Patent and Trademark Office (“USPTO”) for its lead asset SPC-15, demonstrating its commitment to innovative treatments for stress-induced psychiatric disorders, including post-traumatic stress disorder (“PTSD”). The patent focuses on targeting N-methyl-D-aspartate receptors (“NMDARs”) and serotonin type IV receptors […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches Strategic Partnership Program with Segal Trials for Phase 3 MDD Study
January 15, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a neuropsychiatry platform company, announced its first strategic partnership agreement (“SPA”) with Segal Trials as part of its multinational pivotal Phase 3 program for CYB003, targeting Major Depressive Disorder (“MDD”). Segal Trials, a South Florida-based research network specializing in psychiatry and psychedelics, joins Cybin in advancing its Phase 3 […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights 2024 Achievements and Outlines Key 2025 Milestones
January 13, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN), a clinical-stage neuropsychiatry company, summarized its 2024 accomplishments and detailed upcoming 2025 milestones. CEO Doug Drysdale highlighted advancements in its pipeline of tryptamine serotonin receptor agonists, including CYB003, a deuterated psilocin program for major depressive disorder (“MDD”), and CYB004, a deuterated dimethyltryptamine in intramuscular form for generalized anxiety disorder […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Lytham Partners Healthcare Summit
January 10, 2025
Cybin (NYSE American: CYBN) (NEO: CYBN) a clinical-stage neuropsychiatry company, announced that CEO Doug Drysdale will join a fireside chat at the virtual Lytham Partners 2025 Investor Healthcare Summit on Jan. 13. The live webcast begins at 11:30 a.m. ET, with an archived version accessible afterward on the company’s investor relations site. To view the […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Strengthens Patent Portfolio with Approval for PTSD Treatment SPC-15
January 8, 2025
Silo Pharma (NASDAQ: SILO) received a Notice of Allowance from the U.S. Patent and Trademark Office for a key patent supporting its lead asset, SPC-15, an intranasal treatment for PTSD. The patent, expected to be formally issued within 90 days, builds on Silo’s existing intellectual property and expands protection for SPC-15, a serotonin 5-HT4 receptor […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Progress in Mental Health and Chronic Pain Treatments
January 2, 2025
Silo Pharma (NASDAQ: SILO), a biopharmaceutical company specializing in innovative drug formulations and delivery systems, issued a shareholder letter outlining advancements for its leading assets, SPC-15 and SP-26. SPC-15, an intranasal treatment for PTSD and stress-induced anxiety, is progressing toward FDA submission in 2025, supported by promising preclinical results for PTSD, eating disorders, and depression. […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Ketamine Implant Development with Pharmacokinetic Study
December 18, 2024
Silo Pharma (NASDAQ: SILO), a biopharmaceutical company developing innovative therapeutics, has initiated a pharmacokinetic (“PK”) and tolerability study for its dissolvable ketamine-based implant, SP-26, in collaboration with AmplifyBio. The study will evaluate SP-26, aimed at treating chronic pain and fibromyalgia, in a minipig model over three weeks, focusing on absorption, distribution, metabolism, and excretion (“ADME”). […]